Cart
sales@molnova.com
VTP50469
CAS No. 2169916-18-9
VTP50469( —— )
Catalog No. M23981 CAS No. 2169916-18-9
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 491 | In Stock |
|
| 5MG | 353 | In Stock |
|
| 10MG | 424 | In Stock |
|
| 25MG | 592 | In Stock |
|
| 50MG | 739 | In Stock |
|
| 100MG | 995 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVTP50469
-
NoteResearch use only, not for human use.
-
Brief DescriptionVTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.
-
DescriptionVTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.
-
In Vitro——
-
In VivoAnimal Model:Unconditioned immunodeficient (NSG) mice with MV4;11 cells Dosage:15 mg/kg, 30 mg/kg, and 60 mg/kg Administration:Oral administration; twice a day; for 28 days Result:Was highly efficacious across all dosage levels and all treatment groups had a significant survival advantage over the control group.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|Menin-MLL interaction
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2169916-18-9
-
Formula Weight630.82
-
Molecular FormulaC32H47FN6O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (198.15 mM; Need ultrasonic)
-
SMILESCC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11.
molnova catalog
related products
-
Pamrevlumab
Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
-
CWI1-2
CWI1-2 is a potent IGF2BP2 inhibitor that inhibits its interaction with M6A-modified target transcripts by binding IGF2BP2. CWI1-2 has anti-leukemic activity and can induce apoptosis and differentiation.
-
RSH-7
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
